BRD has long-term health consequences that cost the U.S. cattle industry an estimated $800 million to $900 million annually in medical and treatment expense, reduced animal performance and mortality. It’s also the single biggest killer of newly weaned calves.

“The intranasal administration of Once PMH IN stimulates a strong immune response because vaccine antigens are delivered directly to mucosal surfaces in the nose – the major sites of immune response in cattle,” said Rick Sibbel, D.V.M., Merck Animal Health director of beef cattle technical services.

Studies demonstrate young calves given an intranasal administration of Once PMH IN performed better on body temperature and weight gain measures when compared to calves given a commercial subcutaneous pasteurella vaccine.

“Calves given Once PMH IN also had a dramatically reduced inflammatory protein level response, an indicator of infection and inflammation, which can adversely affect calf performance,” explained Dr. Sibbel.

Once PMH IN is a non-adjuvanted formulation with two dosing options – 1 mL applied in each nostril of the animal or a 2-mL dose delivered in one nostril. Because there is no vaccine injection site, carcass quality is not compromised.

Advertisement

While annual revaccination is recommended, the vaccine can be administered more frequently, depending on the farm’s risk assessment or if the herd faces epidemic conditions. As always, consult your herd veterinarian for specific guidance.

Once PMH IN is available in 10-dose and 50-dose packages. To further assist in vaccine delivery, Merck Animal Health has developed new, less invasive cannula and pump-its, which are available through Merck Animal Health representatives or veterinarians. end mark

– Merck Animal Health news release

PHOTO
Photo courtesy of Merck Animal Health.